Giant cell tumour of bone in the denosumab era

Abstract Giant cell tumour of bone (GCTB) is an intermediate locally aggressive primary bone tumour, occurring mostly at the meta-epiphysis of long bones. Overexpression of receptor activator of nuclear factor kappa-B ligand (RANKL) by mononuclear neoplastic stromal cells promotes recruitment of num...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) 2017-05, Vol.77, p.75-83
Hauptverfasser:	van der Heijden, Lizz, Dijkstra, P.D. Sander, Blay, Jean-Yves, Gelderblom, Hans
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvants Alcohols Antineoplastic Agents - therapeutic use Biocompatibility Biomedical materials Bisphosphonates Bone cancer Bone cements Bone Density Conservation Agents - therapeutic use Bone diseases Bone grafts Bone Neoplasms - drug therapy Bone Neoplasms - radiotherapy Bone Neoplasms - surgery Bone resorption Bone tumors Cells Clinical Trials, Phase II as Topic Combined Modality Therapy Curettage Denosumab Denosumab - therapeutic use Drug therapy Epiphysis Genes, Neoplasm - genetics Giant Cell Tumor of Bone - drug therapy Giant Cell Tumor of Bone - radiotherapy Giant Cell Tumor of Bone - surgery Giant cell tumour of bone Giant cells Grafting Hematology, Oncology and Palliative Medicine Humans Liquid nitrogen Medical treatment Metastases Monoclonal antibodies Mutation - genetics Nuclear engineering Nuclear safety Oncology Pharmacovigilance Phenols Polymethyl methacrylate Polymethylmethacrylate Postoperative Complications - etiology Prostheses Quality of life RANK ligand Sacrum Salvage Stromal cells Substitute bone Surgery Targeted cancer therapy Therapy TRANCE protein Tumors Zoledronic acid
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!